

Table S1: AR/LV (%) and AI/AR (%) for the control, ANV-6L15 and hirudin treated groups and the *p* value for each group vs. control.

	Control	2.5 µg/kg		5.0 µg/kg		10 µg/kg		50 µg/kg		250 µg/kg		Hirudin
subgroup		a	b	a	b	a	b	a	b	a	b	
AR/LV (%)	38.4±3.8	33.1±2.8	39.3±5.7	36.4±7.3	40.9±2.0	34.9±3.7	39.6±2.8	39.6±2.8	36.9±2.5	37.7±4.2	33.3±1.7	34.9±4.2
<i>P</i> vs. control	-	0.07	0.29	0.23	0.28	0.09	0.27	0.29	0.40	0.44	0.11	0.20
AI/AR (%)	40.8±1.1	13.5±0.9	8.9±2.3	10.2±1.2	8.1±4.2	12.7±3.0	7.5±4.1	10.5±1.6	6.1±2.1	5.2±4.1	5.4±4.1	22.1±2.2
<i>P</i> vs. control	-	0.005	0.008	0.004	0.008	0.005	0.01	0.007	0.007	0.005	0.004	0.05

a: ANV-6L15 injection before ischemia

b: ANV-6L15 injection after ischemia

AR/LV (%) for all groups = 37.1±2.6 %